Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Gastric Adenocarcinoma × Trifluridine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm Metastasis 1 Gastric Adenocarcinoma 1 Gallbladder Neoplasms 1 Colonic Neoplasms 1 Bile Duct Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1 tipiracil 1 pembrolizumab 1 cabozantinib 1 andecaliximab 1 Trifluridine 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Irinotecan 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed

20 enrolled 9 charts

Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡